Valuation: Curis, Inc.

Market Cap 11.87M 10.4M 9.58M 8.89M 16.88M 1.13B 17.11M 115M 44.62M 556M 44.59M 43.61M 1.93B P/E 2026 *
-0.19x
P/E 2027 * -0.29x
Enterprise Value 11.87M 10.4M 9.58M 8.89M 16.88M 1.13B 17.11M 115M 44.62M 556M 44.59M 43.61M 1.93B EV / Sales 2026 *
6.78x
EV / Sales 2027 * 0.93x
Free-Float
1,839.37%
Yield 2026 *
-
Yield 2027 * -
1 day-14.31%
1 week-51.06%
Current month-51.06%
1 month-45.65%
3 months-53.54%
6 months-69.59%
Current year-74.12%
1 week 5.04
Extreme 5.0411
11.32
1 month 3.61
Extreme 3.612
11.4
Current year 3.61
Extreme 3.612
24.2
1 year 3.61
Extreme 3.612
40.28
3 years 3.61
Extreme 3.612
360
5 years 3.61
Extreme 3.612
3,616
10 years 3.61
Extreme 3.612
7,440
Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Date Insider Type Main position Quantity % Market Cap.
03-30Buy

Director

10,000 0.0728%
03-19Conversion

Chief Executive Officer

133,333 0.9708%
03-19Conversion

Director

26,667 0.1942%
Change 5-day change 1-year change 3-year change Capi.($)
-14.31%-51.06%-85.32%-98.42% 11.87M
-1.03%+5.24%+2.94%+9.41% 50.25B
-0.06%+1.11%+416.38%+617.53% 40.39B
+1.09%+7.94%+28.39%-3.80% 34.38B
-1.24%+7.18%+26.74%+61.14% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+2.02%+2.55% - - 16.64B
-2.65%+3.58%+72.01%+132.90% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+2.96%+7.61%+104.22%+104.22% 13.75B
Average -1.10%+10.11%+64.98%+97.59% 24.6B
Weighted average by Cap. +0.14%+4.10%+94.99%+140.18%

Financials

2026 *2027 *
Net sales 1.75M 1.53M 1.41M 1.31M 2.49M 167M 2.52M 16.9M 6.58M 81.94M 6.57M 6.43M 284M 12.75M 11.17M 10.28M 9.55M 18.13M 1.22B 18.37M 123M 47.91M 597M 47.88M 46.83M 2.07B
Net income -45.15M -39.54M -36.42M -33.81M -64.2M -4.31B -65.07M -436M -170M -2.11B -170M -166M -7.33B -35.44M -31.04M -28.59M -26.54M -50.39M -3.38B -51.08M -342M -133M -1.66B -133M -130M -5.75B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26-07-07 US$5.110 -13.97% 60,868
26-07-06 US$5.940 -14.31% 160,363
26-07-02 US$6.932 -17.89% 118,674
26-07-01 US$8.442 -19.15% 229,164
26-06-30 US$10.44 +18.12% 637,537
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.940USD
Average target price
280.00USD
Spread / Average Target
+4,613.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock